Director/PDMR Shareholding

Summary by AI BETAClose X

GSK plc has announced transactions involving American Depositary Shares (ADSs) by several Persons Disclosing Major Interests (PDMRs). On January 14, 2026, Non-Executive Director Dr. Hal Barron acquired 2,832.219 ADSs at $50.2949, SVP and Group General Counsel James Ford acquired 285.772 ADSs at $50.2949, and Chief Digital and Technology Officer Shobie Ramakrishnan acquired 344.244 ADSs at $50.2949, all following dividend re-investment. Additionally, on January 9, 2026, President, US Maria Martinez-Davis acquired a total of 246.888 ADSs across two transactions at $50.2200 each, also through dividend re-investment on the New York Stock Exchange.

Disclaimer*

GSK PLC
16 January 2026
 

GSK plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 January 2026

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$50.2949

2,832.219

 






d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2026-01-14

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 January 2026

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$50.2949

285.772

 






d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2026-01-14

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 



 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Maria Martinez-Davis

b)

Position/status

President, US

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 January 2026

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$50.2949

44.836

 






d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2026-01-14

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Maria Martinez-Davis

b)

Position/status

President, US

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 January 2026

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$50.2200

91.071

 



$50.2200

155.817

 






d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2026-01-09

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Shobie Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 January 2026

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$50.2949

344.244

 






d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2026-01-14

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

GSK (GSK)
UK 100

Latest directors dealings